skip to Main Content

Celebrating Progress in Cancer Research and Entrepreneurship!

The AIM-HI Accelerator Fund is fiercely dedicated to accelerating the commercialization of innovative lab breakthroughs into life-saving new therapies and technologies. These words evoke a pathway. A pathway of progress that connects cancer research lab breakthroughs to game-changing novel technologies.…

2021 Women’s Venture Competition Announced Semi-Finalists!

The AIM-HI Accelerator Fund just announced 10 semi-finalists for the 2021 Women’s Venture Competition! These oncology companies have been selected from among an exceptional pool of applications submitted globally by women scientist-entrepreneurs. Decision making was led by a selection committee…

Making Cancer Patient Clinical Trial Recruitment & Engagement Easier

Are you struggling to increase clinical trial awareness, recruitment, and participant retention for your oncology drug trials? Building up an efficient pre-screening process becomes an urgent task for companies to connect with potential participants; keep them engaged through the trial…

Applications Open for the 2021 AIM-HI Women’s Venture Competition!

Today is International Women’s Day. In honor of the occassion, the AIM-HI Accelerator Fund (AIM-HI) would like to highlight for you our venture philanthropy effort to provide critically needed seed funding to an underserved population: women scientist-entrepreneurs devoted to address…

Together, All of Our Actions Matter!

Every year, people around the world connect on a special day to support and remember the families and individuals affected by cancer. This day is called World Cancer Day, on February 4th. Over the past two decades, World Cancer Day…

AIM-HI Women’s Venture Competition Sponsor: Microsoft

The AIM-HI Accelerator Fund sincerely thanks Microsoft for being a generous sponsor and supporting our inaugural Women’s Venture Competition program to provide various opportunities to women-led oncology start-ups! Only 2% of all venture money go to women-led early stage companies.…

AIM-HI Portfolio Company Profile: Rasio Therapeutics

Serial entrepreneur Ken Malone, Ph.D., and his team of scientists and business executives are at the forefront of developing cutting-edge biohealth companies. Malone is the Chairman of the Board of Directors of Rasio Therapeutics, a start-up which is bringing innovative…

Back To Top